Find an MSK Doctor or Cancer Specialist
Dana E. Rathkopf, MD

Dana E. Rathkopf, MD

Genitourinary Oncologist

Areas of Expertise

My Specialties

  • Prostate Cancer
  • Clinical Trials
View all
Dr. Rathkopf's Office Information
Languages: English

Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.
Back to top
Share

About Me

What I Do at MSK
  • Attending Physician
  • Chair, Research Council
Get To Know Me

I am a board-certified medical oncologist who treats people with prostate cancer and other genitourinary cancers. My primary focus is on the medical treatment of men with advanced or high-risk prostate cancer. I have been doing this work for more than a decade.

This provider is part of a team that was ranked #1 in the nation for Urology Cancer Care this year by U.S. News & World Report.
Read more

I also develop and design clinical trials testing new treatments for men with prostate cancer. I have had a leadership role in the development of clinical trials using androgen receptor (AR)-targeted therapies (such as abiraterone, enzalutamide, and apalutamide) for patients with advanced prostate cancer. The survival benefits shown in these trials changed the standard of care for patients with advanced disease. I am now focused on improving outcomes for patients in need of additional treatments by using new AR-directed therapies and combinations of targeted agents.

On a national level, I am the site principal investigator at Memorial Sloan Kettering Cancer Center for the Department of Defense Prostate Cancer Clinical Trials Consortium (PCCTC), an initiative designed to increase patient access to clinical trials across the country. I also serve as Chair of the Research Council at MSK, which is charged with ensuring the scientific merit and progress of our patient-facing research portfolio.

Although I do a lot of work with clinical trials in an effort to bring new and effective treatment options into clinical practice, my first priority is always my patients. Many of them ask me why I became interested in a disease that only affects men. In addition to my interests in the unique biology of the prostate cancer disease pathway and the opportunity to work with extraordinary mentors and colleagues, I am also a daughter, wife, and mother of three sons. The choice to pursue a career in prostate cancer was an easy one for me.

Areas of Expertise

My Specialties

  • Prostate Cancer
  • Clinical Trials
Education & Honors

Education

  • MD, Tulane School of Medicine

Residencies

  • Internal Medicine - New York University Hospital

Awards and Honors

  • Top Doctors New York Metro Area, Castle Connolly (2023)
  • Exceptional Women in Medicine Award, Castle Connolly (2023)
  • Castle Connolly: America's Top Doctors (2023)
  • Castle Connolly: New York Magazine Top Doctors (2019-2022)
  • Excellence in Internal Medicine, American College of Physicians
  • ASCO/AACR (American Association for Cancer Research) Workshop: Methods in Clinical Cancer Research, ASCO Merit Award
  • Prostate Cancer Foundation Young Investigator Award
  • SU2C Catalyst Award

Fellowships

  • Medical Oncology/Hematology - Memorial Sloan Kettering Cancer Center
  • Medicine - Weill Cornell Medical College

Board Certifications

  • Medical Oncology

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Aetna

In Network Coverage Type
HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (City of NY retirees only, starting 9/1/23)

In Network Coverage Type
PPO

Blue Cross Blue Shield Federal Employee Program

In Network Coverage Type
HMO, PPO

Blue Cross Blue Shield New York

In Network Coverage Type
PPO, POS, EPO, HMO

Blue Cross Blue Shield states outside of NY/NJ

In Network Coverage Type
HMO, EPO PPO, POS

Blue Cross Health Plus

In Network Coverage Type
HMO

Carrum Health

In Network Coverage Type
Supplemental

Cigna

In Network Coverage Type
PPO, POS, HMO

Connecticare

In Network Coverage Type
POS, EPO, HMO

Emblem

In Network Coverage Type
PPO, POS, EPO, HMO

Emblem Essential

In Network Coverage Type
HMO

Emblem Medicare Advantage

In Network Coverage Type
PPO, HMO

Empire Blue Cross Medicare Advantage

In Network Coverage Type
PPO, HMO, DSN

Empire Essential

In Network Coverage Type
HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

In Network Coverage Type
PPO

Fidelis

In Network Coverage Type
HMO, EPO

Fidelis Managed Medicaid & HARP

In Network Coverage Type
HMO

Fidelis Medicare Advantage

In Network Coverage Type
HMO

First Health

In Network Coverage Type
PPO

Healthfirst

In Network Coverage Type
EPO, HMO, PPO, POS

Healthfirst Managed Medicaid

In Network Coverage Type
HMO

Healthfirst Medicare Advantage

In Network Coverage Type
HMO, PPO

Healthsmart

In Network Coverage Type
PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

In Network Coverage Type
HMO

Horizon Blue Cross Blue Shield New Jersey (PPO)

In Network Coverage Type
PPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

In Network Coverage Type
EPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

In Network Coverage Type
EPO

Horizon Medicare Advantage

In Network Coverage Type
PPO, HMO

Husky CT Medicaid

In Network Coverage Type
State Government

Magnacare

In Network Coverage Type
PPO, POS, EPO

Straight NJ Medicaid

In Network Coverage Type
State Government

Straight NY Medicaid

In Network Coverage Type
State Government

Medicare Part A&B (traditional Medicare)

In Network Coverage Type
Federal Government

Multiplan/Beech Street/PHCS

In Network Coverage Type
Supplemental

MVP

In Network Coverage Type
PPO/OAP

Non-Participating Plans with Out of Network Benefits

In Network Coverage Type
PPO, POS, EPO, HMO

NYC Medicare Advantage Plus for City Employees

In Network Coverage Type
TBD

Oscar

In Network Coverage Type
HMO/EPO

Oxford

In Network Coverage Type
PPO, EPO

World Trade Center Health Program (WTC)

In Network Coverage Type
State Government

Qualcare

In Network Coverage Type
PPO, POS, HMO

Tricare

In Network Coverage Type
PPO, HMO

UMR

In Network Coverage Type
PPO, POS

United Healthcare

In Network Coverage Type
PPO, POS, HMO

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Make an Appointment

Women talking

New Patients

Scheduling an appointment is easy. Click or call 646-497-9068— we’re available Monday through Friday, to (Eastern time)
Make an Appointment

Current Patients

Request an appointment by logging on to MyMSK or calling your doctor’s office. If you aren’t registered for MyMSK, call 646-227-2593 for your Enrollment ID.

Contact and Location

Dr. Rathkopf sees patients at one location.

Office Phone
Location
New York, NY
Sidney Kimmel Center for Prostate and Urologic Cancers
353 East 68th Street New York NY 10065
Get Directions

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Leadership doctors

See all Genitourinary Oncology Service doctors

Clinical Trials

Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomized, double-blind, placebo-controlled phase 3 study

Abiraterone in metastatic prostate cancer without previous chemotherapy

Enzalutamide in metastatic prostate cancer before chemotherapy

Phase 1 study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer

Publications on PubMed

Visit PubMed for a full listing of Dr. Rathkopf’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Dana E. Rathkopf discloses the following relationships and financial interests:

  • AstraZeneca
    Professional Services and Activities (Uncompensated)
  • Genentech
    Professional Services and Activities (Uncompensated)
  • Janssen Research & Development, LLC
    Professional Services and Activities (Uncompensated)
  • Myovant Sciences
    Professional Services and Activities (Uncompensated)

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures

Related topics: